Search

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

How Simulation is Changing the Game in Biotherapeutic Drug Development

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

New affordability initiative with GoodRx for our biosimilar

Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar

African Swine Fever: Important Facts | Boehringer Ingelheim US

Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.

How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US

Click here to learn more about steps that pet owners can take to help prevent Lyme Disease in dogs.

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim Launches External Innovation Hub in China

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

The power of patient advocacy in cancer care

Patients and advocacy organizations agree that patient empowerment is key to quality cancer care

Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US

BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US

BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US

Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline

US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US

EMPA-REG OUTCOME® trial: New analyses show that JARDIANCE reduced the risk of CV death in adults with T2D. View ISI, PI and Med Guide.

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers